Chimeric urokinase type plasminogen activator (uPA)/severely severe combined immunodeficiency (SCID) mice reconstituted with humanized livers are useful for studying hepatitis B virus (HBV) infection in the absence of an adaptive immune response. However, the detailed characterization of HBV infection kinetics necessary to enable in-depth mechanistic studies in this in vivo HBV infection model is lacking. To characterize HBV kinetics post-inoculation (p.i.) to steady state, 42 mice were inoculated with HBV. Serum HBV DNA was frequently measured from 1 minute to 63 days p.i. Total intrahepatic HBV DNA, HBV covalently closed circular DNA (cccDNA), and HBV RNA was measured in a subset of mice at 2, 4, 6, 10, and 13 weeks p.i. HBV half-life (t 1/2 ) was estimated using a linear mixed-effects model. During the first 6 hours p.i., serum HBV declined in repopulated uPA/SCID mice with a t 1/2 5 62 minutes (95% confidence interval [CI] 5 59-67). Thereafter, viral decline slowed followed by a 2-day lower plateau. Subsequent viral amplification was multiphasic with an initial mean doubling time of t 2 5 8 6 3 hours followed by an interim plateau before prolonged amplification (t 2 5 2 6 0.5 days) to a final HBV steady state of 9.3 6 0.3 log copies (cps)/mL. Serum HBV and intrahepatic HBV DNA were positively correlated (R 2 5 0.98). Conclusion: HBV infection in uPA/SCID chimeric mice is highly dynamic despite the absence of an adaptive immune response. Serum HBV t 1/2 in humanized uPA/SCID mice was estimated to be 1 hour regardless of inoculum size. The HBV acute infection kinetics presented here is an important step in characterizing this experimental model system so that it can be effectively used to elucidate the dynamics of the HBV life cycle and thus possibly reveal effective antiviral drug targets. (HEPATOLOGY 2018; 68:473-484).
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M ore than 2 billion people have been infected with hepatitis B virus (HBV) worldwide with 240 million remaining chronically infected, making HBV a leading cause of morbidity and mortality in countries with high prevalence rates.
(1) During acute infection, HBV DNA reaches high levels in blood (up to 10 10 copies [cps]/ mL) within several weeks and almost all hepatocytes become infected. (2) The age at which an individual becomes infected is highly associated with infection outcome, (3) with chronic infection being established in more than 90% of infants and in up to 50% of children aged 1-5 years, but only in 5%-15% of adults. (4) Although the immune response has a pivotal role in controlling the infection, the precise mechanisms are still not known. (5, 6) Abbreviations: cccDNA, covalently closed circular DNA; CI, confidence interval; cps, copies; d -1 , per day; hAlb, human albumin; HBcAg, hepatitis B core antigen; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; IFN, interferon; p.i., postinoculation; SCID, severely severe combined immunodeficiency; t 1/2 , half-life; t 2 , doubling time; uPA, urokinase type plasminogen activator.
The characterization of HBV kinetics during initial acute infection in humans is limited because of the uncertainty regarding the exact time of infection and lack of frequent data sampling. (7, 8) Acute HBV infection has been studied in chimpanzees, but sampling was performed relatively infrequently, on a weekly basis (or longer time intervals), (9) (10) (11) (12) and as of 2011 biomedical research involving chimpanzees has been restricted. Other animal models infected with HBV-related hepadnaviruses, such as woodchuck hepatitis virus, have also provided a limited kinetic picture, but infection dynamics are known to vary among these related viruses. (13) Major attempts have been made to develop small animal models of HBV infection, the most successful being based on liver repopulation with primary human hepatocytes because these are the natural target of HBV (reviewed in a previous work (14) ). One example is the urokinase type plasminogen activator (uPA)/ severely severe combined immunodeficiency (SCID) mouse model, which lack functional B and T cells and thus allow transplanted HBV-permissive human hepatocytes to be maintained in the liver. (15) Such mouse models offer opportunities to study HBV kinetics during the early steps of infection and antiviral treatment in the absence of any confounding effects exerted by an adaptive immune response. (14) In this study, we analyzed the detailed virus kinetics during acute HBV infection in chimeric uPA/SCID mice from infection initiation to steady state. We were able to identify distinct phases of infection, indicating a rapid initial virus decline from the serum and multiphasic resurgence until reaching steady state. Because of very frequent blood sampling, it was also possible to estimate the rate of HBV clearance from blood.
Materials and Methods

MICE
Mice with humanized liver were produced as described. (15) HBV DNA cps and observed from baseline until day 51 p.i. Group D included 31 humanized mice transplanted with human hepatocytes from different donors (2YF, n 5 2; 5YM, n 5 25; 1YF, n 5 4). All animals in this group were inoculated with 10 4 HBV DNA cps. Longitudinal serum viral DNA was measured in these animals from day 7 to 63 p.i. or until they were sacrificed at 2, 4, 6, 8, 10, or 13 weeks p.i. Supporting Table S1 only includes the 9 animals for which the
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complete time course of serum viral DNA measurements were obtained; the other 22 animals were sacrificed as indicated above in order to measure intrahepatic total HBV DNA, HBV covalently closed circular DNA (cccDNA), and HBV RNA. Within the different groups, serum HBV DNA sampling frequency ranged between 30 minutes and 9 days with sampling in the different groups beginning as soon as 1 minute p.i. and continuing through 63 days after inoculation. All animal protocols described in this study were performed in accord with the Guide for the Care and Use of Laboratory Animals and approved by the Animal Welfare Committee of Phoenix Bio Co., Ltd.
INOCULATION WITH HBV DNA
The original virus (HBV genotype C), provided by Dr. Sugiyama, (16) was used to create the viral stock for these experiments by amplifying the virus in uPA/ SCID chimeric mice. Specifically, after observing stable high-level HBV viremia in inoculated mice, serum was collected and pooled for the present study. Serum containing 10 4 -10 8 copies of HBV DNA was intravenously injected into humanized uPA/SCID mice. As in our previous study, (17) mice with humanized livers had human albumin (hAlb) levels of 4.2-15.0 mg/mL (corresponding to a replacement index of 56%-93%) at 7 to 11 weeks after human hepatocyte transplantation.
EXTRACTION AND QUANTIFICATION OF SERUM HBV DNA
DNA was extracted from 10 lL of serum by the Smitest Ex-R&D Nucleic Acid Extraction Kit (Medical & Biological Laboratories Co, Ltd, Nagoya, Japan) and was dissolved in 20 lL of nuclease-free water (Life Technologies Japan Ltd., Tokyo, Japan). HBV-DNA copy numbers were determined by quantitative real-time PCR (qRT-PCR) as reported previously. (18) 
QUANTIFICATION OF HUMAN SERUM ALBUMIN
Because hAlb concentration in serum correlates with the degree of human hepatocyte repopulation observed by human-specific antibody staining of liver sections, (15) hAlb concentration in mouse serum was measured by latex agglutination immunonephelometry test (LX Reagent "Eiken" Alb II; Eiken Chemical Co., Ltd., Tokyo, Japan). These hAlb levels were used to estimate the replacement index of human hepatocytes in mouse livers as described. (19) Levels of human serum albumin were measured as soon as 1 minute after inoculation and then at weekly intervals or less up to 63 days after HBV inoculation.
EXTRACTION AND QUANTIFICATION OF INTRAHEPATIC HBV DNA
Total DNA was extracted from approximately 20 mg of liver independently in two laboratories using DNeasy Blood and Tissue Kit (Qiagen K.K., Tokyo, Japan), according to the instruction provided by the supplier or by phenol chloroform extraction as described. (20) DNeasy Blood and Tissue Kit isolated DNA (50 ng) was amplified by the ABI Prism 7500 sequence detector system (Applied Biosystems Japan Ltd., Tokyo, Japan) using TaqMan PCR Core Reagents (Applied Biosystems Japan Ltd.). The amplification conditions for HBV DNA and cccDNA were described in previous reports respectively. (18, 21) The following primers were used: total HBV (forward primer: 5 0 -CACATCAGGATTCCTAGGACC-3 0 , (19) cccDNA (forward primer:
. Phenol chloroform isolated HBV DNA was quantified by qPCR amplification of 30 ng of liver DNA using an Applied Biosystems 7300 real-time thermocycler (Applied Biosystems) for total HBV, (22) cccDNA, (23) and human telomerase reverse transcriptase (hTERT; forward primer: 5 0 -AAAATAGCTGGAAC TGCAGACA-3 0 , reverse primer: 5 0 -AAGCAAAGC TACAGAAACACTCA -3 0 ). HBV-DNA levels were determined relative to standard curve comprised of serial dilutions of a plasmid containing the HBV genome. HBV DNA copies per cell were then determine relative to single genome copy hTERT gene in each sample.
EXTRACTION AND QUANTIFICATION OF INTRAHEPATIC HBV RNA
Total cellular RNA was isolated by the guanidine thiocyanate method using standard protocols. (24) One microgram of purified RNA was used for complementary DNA synthesis using the TaqMan reverse transcription reagents (Applied Biosystems), followed by SYBR green RTqPCR using the total HBV primers indicated above and an Applied Biosystems 7300 realtime thermocycler (Applied Biosystems). HBV-RNA levels were determined relative to standard curve comprised of serial dilutions of a plasmid containing the HBV genome and normalized to human glyceraldehyde 3-phosphate RNA (forward primer: 5 0 -CAAG ATCATCAGCAATGCCT-3 0 , reverse primer: 5 0 -AGGGATGATGTTCTGGAGAG-3 0 ).
IMMUNOSTAINING FOR HEPATITIS B CORE ANTIGEN
Pieces of liver from HBV-infected mice were fixed with formalin and embedded in paraffin blocks for immunohistochemical staining. Five-micrometer-thick liver sections were subjected to immunostaining using an antibody against hepatitis B core antigen (HBcAg; DAKO Diagnostika, Hamburg, Germany). The antibodies were visualized with EnVision System horseradish peroxidase (DAKO) and 3,3 0 -diaminobenzidine substrate.
(17)
STATISTICAL ANALYSES
Data are expressed as arithmetic mean 6 SD or median value with range. Logarithmic base 10 values of HBV DNA were used throughout the analysis. Statistical analyses and linear regression were computed with Excel 2010 and R (version 3). Linear regression and linear mixed-effects models (R version 3, package nlme) were used to estimate the slopes characterizing virus and albumin kinetics. P values <0.05 were considered statistically significant. Kruskal-Wallis tests were used to compare intergroup differences. Spearman rank correlation was used to evaluate the relationship between two quantitative variables.
Results
Monitoring HBV infection from inoculation to steady state revealed seven different viral kinetic phases independent of HBV inoculum dose or hepatocyte donor (Fig. 1B) . All of these distinct kinetic stages were observed in the group C mice (phases 1-7) and confirmed by the early kinetics observed in group A (phases 1-5) and group B (phases 1-6) and the late kinetics observed in group D (phases 6-7).
RAPID SERUM HBV CLEARANCE (PHASE 1)
Serum HBV DNA in chimeric mice (groups A, B, and C) was measured frequently (1 minute, 30 minutes, and then 1, 2, 3, 5, 6, 12, and 18 hours p.i.). Whereas mice across these three groups displayed dose dependence in viral load, all exhibited a doseindependent rapid decline in HBV-DNA levels within first 6 hours p.i., with an average decrease rate of 7.3 6 0.9 log10/day corresponding to a mean half-life (t 1/2 ) of 62 6 7 minutes ( Fig. 2 ; Supporting Table S1 ). A mixed-effects model was used to calculate the initial 6-hour exponential virus decay and estimate the HBV clearance rate and its confidence interval (CI). These estimates correspond to a virus serum t 1/2 of 63 minutes (95% CI, 59-67).
SLOWDOWN OF SERUM HBV CLEARANCE FOLLOWED BY A LOWER VIRAL PLATEAU (PHASES 2-3)
Between 6 and 24 hours p.i. (18 hours) HBV could not be detected in 5 of 11 groups A-C mice monitored during this time period, but in the remaining mice the initial rapid decline of HBV slowed to 2.6 6 0.9 log10/day, which corresponds to a mean half-life of 3.6 6 1.8 hours (Fig. 3A, phase 2 ). Viral decline ended in a lower plateau that lasted from approximately day 1 to day 3 p.i. (Fig. 3A, phase 3) . Only the 5 mice that were inoculated with 10 8 HBV DNA copies remained HBV detectable during this 2-day viral plateau with an average 4 6 0.3 log10 HBV DNA cps/mL and slope constant between -0.01 and 0.17 log10/day (Supporting Table S1 ).
RAPID RESURGENCE OF SERUM HBV AND INTERIM PLATEAU (PHASES 4-5)
After the above-described lower viral plateau, serum HBV levels increased in the 9 mice that became productively infected (Figs. 1B and 3A, phase 4). In mice inoculated with 10 7 or 10 8 HBV genome copies, this amplification phase could be clearly identified starting between days 2.5 and 3 p.i. and lasted 1-3 days (Fig.  3A, black lines) . Whereas the 2 mice that received 10 6 HBV genome copies exhibited a delay in the initiation of this phase, the slope increase was similar in all animals with an average of 1.1 6 0.5 log10/day (doubling ) and corresponding phases noted in black; mice inoculated with a low HBV dose (i.e., 10 4 ) and corresponding phases noted in gray. Abbreviations: Ph, phase; Grp, group. (Fig. 3A, gray lines) . Unexpectedly, after this brief exponential amplification, HBV DNA increased transiently, slowed, and/or exhibited an interim plateau with a median duration of 3 days starting between days 4 and 6 p.i. This phase 5 plateau was detected in all group B and C mice observed throughout this time period (Fig. 3A, phase 5) . The median HBV doubling time during this period was 3 days with a median increase rate of 0.05 log10/day (ranging from -0.19 to 0.2 log10/day). Notably, serum HBV levels were recorded starting at day 7 p.i. in group D mice and evidence of this plateau period was observed in some of these mice (Fig. 3B, gray lines) , but the data available were not complete enough to be included in the slope calculations for phase 5 (Supporting Table S1 ).
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LONG-TERM SERUM HBV AMPLIFICATION FOLLOWED BY VIRAL STEADY STATE (PHASES 6-7)
Following this interim viral plateau, all mice entered an extended phase of continuous viral expansion (Figs. 1B and 3B, phase 6 ). In this phase, a clear correlation between virus level and inoculum dose was observed. For the mice in groups B and C, this amplification period began 9 days p.i. (median; Fig.  3B , black lines and arrows). In the group D mice who received a lower 10 4 HBV-DNA genome inoculum, the beginning of phase 6 was later (median day 18) and exhibited variability in the viral load and kinetics that appeared to be related, in part, to the different lots of human hepatocytes utilized (Fig. 3B , gray lines and arrow). Strikingly, however, the average slope of viral amplification in all 13 mice across groups was 0.15 6 0.04 log10/days (Supporting Table S1 ), corresponding to a mean viral doubling time of 2 6 0.5 days. The observation period for group B mice ended during phase 6, but the median duration of this period for the remaining 11 group C and D mice who were observed through this period was 28 days.
The final kinetic phase observed was viral steady state (Figs. 1B and 3B, phase 7) . Steady-state HBV serum levels were reached in all group C mice between days 35 and 42 p.i. (median 5 day 35; Fig. 3B , solid black line). Again, the kinetics were delayed and more variable in the low-inoculum-dose group D mice, where steady-state infection was achieved between 42 and 56 days p.i. (median 5 day 49; Fig. 3B, gray  lines) . However, the 9.3 6 0.3 log10 HBV DNA copies/mL steady-state levels obtained in all mice was independent of the initial HBV inoculation dose ( Fig.  3B ; Supporting Table S1) or hepatocyte donor ( Fig.  4A ; P 5 0.13). A significant correlation (r 5 0.64; P 5 0.02) was found between HBV-DNA level at steady state and hAlb at time of HBV inoculation (Fig.  4B) , which could partly explain the slightly higher HBV steady-state levels (Fig. 4A) in the mice that received the 5YM hepatocytes (P 5 0.03; Fig. 4C ).
As expected, serum hAlb levels remained relatively stable during the entire infection period, with the change in hAlb during the long-term observation period for groups C and D fluctuating between -3.8 and 3.7 mg/mL with a median value of 0.0 mg/ mL   FIG. 4 . Associations among hepatocyte donor, steady-state serum HBV DNA, and baseline human albumin levels. (A) Steady-state HBV-DNA levels in humanized chimeric mice by donor group (1YF, n 5 4; 2YF, n 5 6; 5YM, n 5 3; P 5 0.06), (B) a significant correlation between HBV-DNA level at steady state and hAlb at HBV inoculation (r 5 0.64; P 5 0.02; n 5 13), and (C) baseline human serum albumin levels in humanized chimeric mice by donor group (1YF, n 5 4; 2YF, n 5 6; 5YM, n 5 3; P 5 0.01). Medians in (A) and (C) are represented by horizontal lines.
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CORRELATION BETWEEN SERUM AND INTRAHEPATIC HBV LEVELS
To examine the association among serum HBV DNA, intrahepatic total HBV DNA, HBV cccDNA, HBV RNA, and intracellular HBcAg staining, group D chimeric mice with humanized livers (donor 5YM) were sacrificed at 2 (n 5 3), 4 (n 5 4), 6 (n 5 4), 8 (n 5 4), 10 (n 5 2), and 13 (n 5 5) weeks after inoculation. Two weeks p.i. serum HBV DNA and intrahepatic HBV RNA were detectable; however, were below the limit of quantification ( Fig. 5A and C) . After 4 weeks p.i. serum HBV DNA, total intrahepatic HBV DNA and intrahepatic HBV RNA could be quantified in all mice, whereas intrahepatic cccDNA was detected only in mouse #7, which exhibited the highest serum and intrahepatic HBV DNA (Fig. 5A-D) . By week 6 p.i., all mice had cccDNA detected, and from week 8 onward cccDNA was quantifiable (Fig. 5D ). Strong correlations were found among the levels of serum HBV DNA and intrahepatic HBV DNA (Fig. 6) . To compare possible intracellular differences between group 4 mice that received hepatocytes from different donors, total intrahepatic HBV DNA, cccDNA, and the ratio of cccDNA to HBV DNA in the liver of all mice sacrificed at week 13 groups (2YF [n 5 2], 5YM [n 5 5], and 1YF [n 5 4]) were compared, but no difference (P > 0.05) among three different hepatocyte donor groups was observed (Supporting Fig. S1 ). Finally, immunostaining of liver samples for HBcAg performed in 3 mice at weeks 2, 8, and 10 p.i. (Fig. 7) qualitatively showed a similar pattern of slow HBV expansion. Specifically, on the cellular level, only a few HBV-positive cells could be found near the portal vein at week 2 p.i. (Fig. 7A, arrows) , concomitant with detected, but nonquantifiable, serum HBV DNA. By week 8, when serum HBV DNA had increased to 2.7 3 10 7 cps/mL, an increased number of HBVpositive cells was observed, which could be found throughout the liver (Fig. 7B, arrows) . Then, at week 10, when serum HBV DNA had reached steady state (2.5 3 10 9 cps/mL), the majority of cells were HBV positive (Fig. 7C) . were infected with HBV and necropsied at 2 (n 5 3), 4 (n 5 4), 6 (n 5 4), 8 (n 5 4), 10 (n 5 2), and 13 (n 5 5) weeks after inoculation. Real-time qPCR was performed to measure the levels of (A) serum HBV DNA, (B) total intrahepatic HBV DNA, (C) total intrahepatic HBV RNA, and (D) intrahepatic cccDNA. Detected (*) but lower than quantification (----) and not determined (#).
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Discussion
Currently, mice repopulated with human hepatocytes are the only small animal model available for the study of HBV infection; however, detailed analysis of HBV infection kinetics in this model has been lacking. To provide a more complete characterization of this valuable HBV infection model and enable future mechanistic studies and mathematical modelling necessary to elucidate the dynamics of the HBV infection in humanized chimeric mice, we monitored HBV infection at frequent time intervals starting immediately post-inoculation. Quantification of serum HBV DNA allowed us to estimate the HBV clearance rate from circulation and characterize subsequent HBV amplification kinetics to steady state in uPA/SCID mice with humanized livers. Whereas HBV acute infection was previously described in humans (7, 8, (25) (26) (27) (28) and chimpanzees (10, 11, 29, 30) by infrequent sampling, the frequent sampling possible in this experimental system has allowed for the (1) measurement of viral decline kinetics immediately following high-dose inoculation, (2) estimation of the eclipse phase length (i.e., the time between infection and detection of new virions released into circulation), and (3) characterization of the kinetic pattern of subsequent HBV amplification to steady state, which we unexpectedly found to be multiphasic.
HBV clearance rates from blood of chronically infected subjects have been previously estimated during antiviral treatment in which intracellular HBV production was inhibited with antivirals such as interferon (IFN)-alfa, lamivudine, or entecavir. The median t 1/2 observed was 21 and 9 hours in hepatitis B e antigen (HBeAg)-positive and HBeAg-negative patients, respectively, with less than 1 order of magnitude variation among patients (summarized in a previous work (31) ). In contrast, performing mathematical modeling of baseline serum and intrahepatic HBV DNA measured from 80 untreated chronically active HBV patients, Dandri et al. estimated a much shorter median t 1/2 of 46 minutes in HBeAg-positive patients and 2.5 minutes in HBeAg-negative patients, respectively, with a strong inverse correlation between baseline viremia and HBV t 1/2 .
(32) Using a different, more direct strategy, in the current study HBV clearance from blood was estimated based on the initial disappearance of virus after intravenous inoculation. During the first 6 hours p.i., HBV was cleared from blood with a t 1/2 of 1 hour independent of inoculum size, which ranged from 10 4 to 10 8 cps/mL ( Fig. 2A) . These findings indicate a shorter HBV t 1/2 than was estimated during the drug perturbation experiments in chronically infected patients. Notably, this difference could be related to the differences between acute and chronic infection and/or differences between mice and humans. Our initial 1-minute postinoculation HBV measurements when extrapolated for total blood volume in mice accurately reflect the input inoculation dose, suggesting virtually instantaneous distribution of the viral inoculum throughout the blood. Theoretically, clearance immediately after viral inoculation may include some initial redistribution/ clearance of virus from blood into tissues, a feature that does not occur during chronic infection in which viral equilibrium between blood and tissue has already been established. Interestingly, however, the short HBV t 1/2 we observed herein is in line with the Dandri et al. modeling estimates in HBeAg-positive patients. (32) Under these conditions in humanized mice, we did not observe any correlation between inoculation dose and HBV clearance rate. However, to confirm whether an inverse correlation between baseline viremia and HBV t 1/2 uniquely exists after the establishment of HBV steady state (as suggested by Dandri et al. (32) ) would require analogous drug perturbation experiments in the chimeric mouse model system. Notably, these should ideally be performed with antivirals that block HBV secretion as we recently demonstrated in the case of hepatitis C virus (HCV). (33) Specifically, a nonstructural 5A inhibitor, which rapidly/directly blocks HCV assembly/secretion, was able to reveal a much shorter HCV t 1/2 (45 minutes) compared to previous HCV t 1/2 estimates (3 hours) made using drugs such as IFN that mainly block intracellular HCV-RNA replication. (33) In the 5 mice inoculated with 10 8 HBV DNA, copies viral decline p.i. ended in a low viral plateau that lasted approximately 1-3 days p.i. (mean, 4 6 0.3 log cps/mL; Fig. 3 ). Assuming that the observed viral plateau is maintained by equal viral production and clearance, the duration of the cellular eclipse phase (defined as the time interval from when a cell gets infected until the time virus is secreted) would have to be approximately 1 day given that the viral plateau initiated approximately 1 day p.i. However, if the observed viral plateau is not maintained by viral production and clearance, but some other virion dynamics (e.g., HBV that initially bound to cells but then is released back into circulation as has been observed for human immunodeficiency virus, which reversibly binds to follicular dendritic cells (34, 35) ), then an eclipse phase of at least 3 days is possible given that 3 days p.i. rapid viral resurgence was observed, which could only be explained by the production of new virions. If the low viral plateau were attributed to virus in the initial inoculum binding to cells and then being released, a higher inoculum would lead to more virus being bound and released and hence a higher plateau consistent with what was observed. Theoretically, now that we know the appropriate time window to study, the above bound-release hypothesis could be tested and rejected if the viral plateau is not observed when viral replication is blocked by antiviral treatment initiated before or at the time of infection.
The typical serum HBV increase observed in humans based on infrequent sampling from time of infection to peak viremia has been interpreted as exponential (i.e., monophasic on a log-linear scale), with average t 2 of 3 days (range, 2-4). (7, 8, (25) (26) (27) Monophasic HBV amplification has also been reported in acutely infected chimpanzees. (10, 11) In contrast, the initial HBV amplification we observed in this immunocompromised humanized mouse model was fast with t 2 5 8 6 3 hours for 1-3 days, followed by a 1-to 3-day interim plateau before a long-term HBV amplification with t 2 5 2 6 0.5 days. Interestingly, the t 2 during the long-term amplification in these mice is similar to the single-phase t 2 found in humans, suggesting that perhaps the fast HBV expansion (phase 4) and interim plateau (phase 5) detected in our study may have been missed in humans and chimpanzees attributed to a lack of sufficiently frequent sampling and/or lower dose infection, which would potentially be too unsynchronized to detect the distinct phases observed here. In fact, looking carefully in some cases where chimpanzees have been inoculated with high-dose HBV, there is evidence that a multiphasic viral expansion may have occurred (Fig. 1a in Asabe et al. (11) and Fig. 1A in Murray et al. (10) ). The reason for the observed multiphasic HBV expansion in the circulation is not known, but can now be addressed by well-designed studies that include intrahepatic analysis at key time points. As a preliminary assay for possible natural killer cell-mediated HBV-infected cell killing, we measured human alanine aminotransferase (hALT) levels in the serum samples of infected mice compared to uninfected controls, but no correlation between HBV levels and hALT levels were observed (Supporting Fig. S2 ). Although HBV is often referred to as a stealth virus because it does not induce significant innate immune signalling, (36) one possible reason for the shift from rapid to slow multiphasic expansion could be an induction of a transient innate immune response reminiscent of the biphasic HCV increase with a transient viral decline (1 week p.i.) that was observed in acutely HCV-infected chimpanzees, which was proposed to be caused by an observed induction of endogenous type I IFN at 1-2 weeks p.i. (37, 38) It would likewise be interesting to monitor intrahepatic IFN induction during acute HBV infection in future chimeric mouse studies as well as previous HBV chimpanzee experiments if samples are still available.
During the final HBV kinetic phase, virus reached high steady-state levels in all uPA/SCID chimeric mice (9.3 6 0.3 log10 cps/mL) 35-56 days p.i. (Fig.  3B) . Whereas peak serum HBV-DNA levels were observed 60-170 days p.i. in acutely HBV-infected humans (7, 8, 27, 39) and chimpanzees, (10, 11) virus levels typically declined at some point in these immunocompetent hosts rather than remaining at high steady-state levels as observed in uPA/SCID mice, consistent with the crucial role of the adaptive immune response in HBV clearance/control. (2, (10) (11) (12) In addition, no evidence of a significant decline in hAlb was observed during the entire infection period in mice, consistent with the notion that HBV itself is noncytopathic. (40) Interestingly, in chimpanzees, the size of the viral inoculum was shown to contribute to the viral kinetics during acute infection and infection outcome, that is, persistence or clearance. (11) In the current study, we investigated the role of inoculum dose on viral kinetics in the absence of an adaptive immune response and found that inoculum size had no effect on HBV initial clearance rate from blood post-inoculation, the viral doubling time during the HBV expansion phases (phases 4 and 6), the length of the interim plateau (phase 5), or viral steady-state levels (phase 7). The most evident effect of low virus dose was simply a delay in detection of initial virus expansion (phase 4), which subsequently delayed all other kinetic phases. This seems to indicate that the adaptive immune response is not only important in HBV clearance, but also that the interplay between virus dose and the adaptive immune response is additionally a major determinant of HBV infection kinetics. Although the development of an adaptive immune response to HBV is relatively slow and thus likely does not affect very early HBV infection kinetics, the chimeric uPA-SCID model does provides an advantage because it ensures that fundamental HBV infection dynamics can be analyzed in the absence of this variable confounding factor. The study of HBV immunology certainly is of interest, but while such immunocompetent models are being developed, the simplicity of the uPA-SCID model provides a particular advantage for many needed molecular virology studies.
Whereas the distinct phases defined in this study highlight key time points post-inoculation that are of particular interest for more detailed intracellular analyses and provide a basis for determining what types of analyses might be most informative, our initial analysis found that intrahepatic total HBV DNA, cccDNA, and RNA correlate with serum HBV DNA during infection in uPA/SCID mice (Figs. 5 and 6), consistent with findings in 3 acutely HBV-infected chimpanzees. (10) Whether intrahepatic HBV-RNA and DNA levels exhibit the same multiphasic amplification pattern will require more frequent intrahepatic sampling, but meanwhile northern blotting analysis suggests that early in infection expression levels of HBV 3.5 kb of RNA was more pronounced than the hepatitis B surface mRNAs (Supporting Fig. S3 ), an unexpected finding that needs to be further explored. Also in agreement with chimpanzee data, (2) at week 10 (at which time serum HBV levels had reached steady state) most cells were HBV positive. Notably, immunostaining for HBcAg in the liver at the interim weeks 2 and 8 reveal that during the rapid viral expansion (i.e., week 8), HBV-infected cells appear not to form clusters, but rather were spatially distributed, suggesting that virus spread primarily occurs by diffusion of extracellular virus to nonadjacent cells as reported for in vitro duck HBV. (41) This is in contrast to the clusters/foci observed in HCV-infected livers, which has been attributed to direct cell-to-cell spread or virus released from one cell preferentially infecting its neighbors. (42) (43) (44) Importantly, with the enhanced characterization of the uPA-SCID chimeric mouse HBV infection model presented here, we are now better poised to determine whether HBV has the capacity to spread cell to cell and address other clinically relevant questions.
In summary, we characterized HBV kinetics in blood and liver from the time of inoculation until steady state in uPA/SCID mice with humanized livers. We found that immediately after inoculation, the HBV half-life in blood is approximately 1 hour. Our work also revealed an unexpectedly multiphasic viral amplification in the serum in the absence of adaptive immune response. This detailed viral kinetic analysis is an important starting point for developing mathematical models of HBV infection in the absence of an adaptive immune response, but in the presence of an innate response, which perhaps contributes to the observed multiphasic pattern of HBV-DNA amplification, thus revealing further insights into the interaction between HBV and its host.
